|
Istaroxime in Heart Failure: New Hope or More Hype
G. William Dec
You have reached the most complete version of this article accessible without further authentication.
More complete versions are available.
Link to article
|
Article topics:
- Pharmacology..Heart Diseases (Drug Development)
- Medicine..Epidemiology
- Religious Studies..Death
- Medicine..Mortality and Morbidity
- Sociology..Mortality
- Neuroscience..Adenosine
- Medicine..Cardiotonic Agents
- Medicine..Cardiac Output
- Physiology..Blood Pressure
- Medicine..Etiology
Related Article
-
Hemodynamic, Echocardiographic, and Neurohormonal Effects of Istaroxime, a Novel Intravenous Inotropic and Lusitropic Agent: A Randomized Controlled Trial in Patients Hospitalized With Heart Failure
- Mihai Gheorghiade, John E.A. Blair, Gerasimos S. Filippatos, Cezar Macarie, Witold Ruzyllo, Jerzy Korewicki, Serban I. Bubenek-Turconi, Maurizio Ceracchi, Maria Bianchetti, Paolo Carminati, Dimitrios Kremastinos, Giovanni Valentini, Hani N. Sabbah for the HORIZON-HF Investigators
J. Am. Coll. Cardiol. 2008 51: 2276-2285.
[Abstract]
[Full Text]
[PDF]
This article has been cited by other articles:

|
 |

|
 |
 
P. S. Pang, M. Komajda, and M. Gheorghiade
The current and future management of acute heart failure syndromes
Eur. Heart J.,
April 1, 2010;
31(7):
784 - 793.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Gheorghiade and P. S. Pang
Acute Heart Failure Syndromes
J. Am. Coll. Cardiol.,
February 17, 2009;
53(7):
557 - 573.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|